Immediate Impact
56 standout
Citing Papers
Cross-priming in cancer immunology and immunotherapy
2025 Standout
Clinical applications of human organoids
2025 Standout
Works of Kai-Wen Lin being referenced
Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors
2024
Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival
2021
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Kai-Wen Lin | 50 | 118 | 92 | 91 | 13 | 407 | |
| Ulrich Thienel | 42 | 28 | 15 | 35 | 13 | 406 | |
| Chiara Marzi | 7 | 126 | 51 | 18 | 30 | 375 | |
| Amanda Fisher‐Hubbard | 21 | 7 | 23 | 174 | 17 | 438 | |
| Biao Cai | 15 | 236 | 19 | 10 | 23 | 372 | |
| Hsu‐Hsia Peng | 5 | 31 | 8 | 7 | 34 | 371 | |
| Nathaniel Wyckoff | 26 | 49 | 24 | 8 | 12 | 385 | |
| Hemat Allam | 13 | 33 | 21 | 8 | 9 | 393 | |
| Yukio Ueda | 3 | 36 | 11 | 60 | 31 | 439 | |
| Alberto F. Goldszal | 5 | 73 | 59 | 25 | 14 | 365 | |
| Zhili Xu | 20 | 14 | 14 | 9 | 24 | 389 |
All Works
Login with ORCID to disown or claim papers
Loading papers...